The VUB-VIB Bio Incubator Brussels ©Thierry Geenen

VUB and VIB launch new Bio Incubator Brussels on VUB campus

Catalyst for collaboration and biotechnological innovation

The Vrije Universiteit Brussel (VUB) and VIB have joined forces to launch the brand-new Bio Incubator Brussels (BIB) on the green VUB Main Campus in Etterbeek. This innovative hub brings together science, technology, and entrepreneurship to transform groundbreaking biotechnological advancements into new companies. Start-ups in the fields of biotechnology, pharmaceuticals, and health technology can now utilize this facility, which offers ready-to-use lab and office spaces. The VIB Nanobody Core Facility was the first to move in.

The bio-incubator was established on the initiative of and with financial support from the VIB-VUB Center for Structural Biology. This research center, led by Jan Steyaert and Han Remaut, has a strong track record of successful biotech spin-offs, such as Ablynx, Biotalys, and Confo Therapeutics.

“With this new bio-incubator, we aim to facilitate the creation of start-ups in their early stages and strengthen the link between our lab and our spin-offs,” says Prof. Jan Steyaert, Scientific Director of the VIB-VUB Center for Structural Biology.

Bridge between innovation and collaboration

The Bio Incubator Brussels offers a stimulating ecosystem for innovation and scientific collaboration. The spaces are equipped with state-of-the-art lab furniture and include shared lab facilities, modern office spaces, and a wide range of support services. These services include mentorship, networking opportunities, and direct access to academic talent and industrial partners closely associated with the university and institute.

Jan Danckaert, rector of the VUB, highlights the incubator’s importance: “The establishment of the Bio Incubator Brussels reinforces the VUB’s role in translating scientific research into societal and economic applications. It is a critical platform that will shape an ecosystem for companies and scientists to collaborate on solutions and applications in life sciences and health technology that will make a difference in the near future.”

VIB Nanobody Core Facility takes the lead

The first organization to set up in the bio-incubator is the VIB Nanobody Core Facility. This facility specializes in developing nanobodies, unique antibodies used in the biomedical and pharmaceutical sectors to create new treatments.

Dr. Gholamreza Hassanzadeh Ghassabeh, head of the Nanobody Core Facility, expressed his enthusiasm: “Bio Incubator Brussels provides us with the opportunity to further develop our research on nanobodies in a stimulating environment, surrounded by experts and companies who can support our innovation process. This is a fantastic chance to link scientific progress with commercial applications that can make a real impact on healthcare.”

For more information and to arrange a visit, go to https://www.vubtechtransfer.be/bio-incubator-brussels-bib.

Pictures © Thierry Geenen

 


Contact

David Moreels

​Incubator Manager VUB 

​0488 66 67 95 

david.moreels@vub.be 

Jan Steyaert

​Scientific Director VIB-VUB Center for Structural Biology

​0495 27 02 48 

jan.steyaert@vub.be

www.steyaertlab.be ​ ​ 

 

 

 

 

 

Share

Latest stories

Website preview
New research brings personalized treatment for Parkinson’s disease a step closer
Leuven, 5 May 2026 – A new study led by researchers from VIB and KU Leuven shows that Parkinson’s disease can be divided into distinct subtypes, helping explain why a single treatment does not work for all patients. Using an machine-learning-driven analysis, the team identified two main groups and five subgroups of the disease, marking an important step toward more personalized therapies. The findings were recently published in Nature Communications.
press.vib.be
Website preview
New lung cancer model reveals how tumor location shapes the immune response
Brussels, 27 April 2026 – Researchers at VIB and VUB have developed a powerful new way to study how the immune system behaves inside lung tumors. By combining a patient-relevant mouse model with single-cell technologies, the team provides one of the most comprehensive immune maps to date of lung adenocarcinoma, which is the most common subtype of lung cancer. Their work appears in Nature Communications.
press.vib.be
Website preview
Molecular keyhole sheds light on pain and epilepsy
Leuven, 21 April 2026 – Researchers at VIB, VUB, and KU Leuven have identified a tiny binding site, a molecular ’keyhole’, in the TRPM3 ion channel, a crucial sensor in pain signaling. TRPM3 is also linked to rare neurodevelopmental disorders and epilepsy. In a recent study published in Nature Communications, the researchers found that even the slightest change in this keyhole can radically switch the channel’s behavior, explaining how certain mutations can flip the effects of drugs.
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be